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DAILY UNM GLOBAL HEALTH COVID-19 BRIEFING
May 27-28, 2020

Executive Summary
NM Highlights: NM governor’s press briefing. NM restaurants reopening. Navajo Nation updates. NM case
count. CVS new testing sites. Mask Madness competition updates. Limited campus will return at UNM.
US Highlights: CA becomes fourth state with 100,000 known infections. Model shows relationship between
COVID-19 and crime.
International Highlights: E.U. countries ban hydroxychloroquine. Will E.U. economic collapse create an historic
centralized government?
Economics, Workforce, Supply Chain, PPE: Mental health impact. Face mask itch. Remote postdoctoral
fellowships.
Epidemiology Highlights: Black vs. white hospitalization and mortality. African infection rates limited.
Characteristics of COVID patients.
Healthcare Policy Recommendations: South Korea focuses on a single metric: time from symptom onset to
hospitalization/quarantine. Full flight travel ban effectiveness. The role of case managers during COVID-19
crisis. Only half of Americans are ready to get vaccinated once the vaccine becomes available: a survey.
Practice Guidelines: Harvard authors’ recommendations on restarting essential surgery during COVID-19
pandemic. UNM Project ECHO response to COVID-19 (includes osteoporosis management recommendations).
Five online COVID-19 treatment simulations.
Testing: Validation of modified viral detection assays across multiple specimen types.
Drugs, Vaccines, Therapies, Clinical Trials: Remdesivir 5 days vs. 10. Anti-platelet therapy. Virtual screenings.
S-HCQ better than R-HCQ. Stem cell therapy. Tocilizumab not effective. HCQ and CQ safety issues. Lopinavirritonavir no benefit. 79 new trials.
Other Science: Apolipoprotein E gene associated with severity. France cardiac arrests double. Lab tests that
predict severity. ER inanimate surface contamination. Long-term SARS and MERS outcomes.
All of our past briefings are maintained in a UNM library repository here.
Our continuously curated practice guidelines in the context of COVID-19 can be found here.
Our continuously curated therapeutic evidence is maintained here.
You may submit content for future briefings here.

NM Highlights


NM Governor and leadership provides updates and announces additional easing of restrictions June 1
Governor Michelle Lujan Grisham gave a live videoconference May 28. NM reached its peak number of new cases/day May 1,
dropping on average thereafter. Dr. David Scrase pointed out that independent site https://www.covidexitstrategy.org/
shows NM one of only 3 states in the green in terms of reopening. The State R0 is now at 1.09. Governor announced that
starting June 1, restaurants may operate dine-in service at 50% maximum occupancy and must use COVID-safe practices. Hair
and nail salons, barber shops, tattoo parlors, and massage services may operate at 25% max occupancy. Indoor malls may
open at 25% of max occupancy, food courts closed. Gyms may operate at 50% maximum occupancy. Drive-in theaters may
open. Hotels may operate at 50% max occupancy. More state parks to reopen, but no camping or congregating on beaches.
14-day quarantine order for airport arrivals amended to permit certain business travel. Retailers and houses of worship
continue to be able to operate at 25% of max occupancy. Bars remain closed. Face coverings must be worn in public settings.
Mass gatherings and congregations prohibited. Stay home as much as possible, particularly if sick or vulnerable. Safe
practices for various reopening activities provided here.



Beginning May 27, most NM restaurants can provide limited outdoor or patio services
The following stipulations apply: no dine-in service may be provided in indoor seating areas; outdoor dine-in service may only
be provided to patrons who are seated; Tables must be placed with at least six feet of distance between one another; no
more than six patrons may be seated at any single table; no bar or counter seating is permitted. Broader reopening is
expected on June 1.



The curve is flattening out on the Navajo Nation
Some positive news came from the Navajo Nation on Tuesday. Although positive cases are still going up, the hospital visits
are down 30-40 percent. "Everyone including the Navajo citizens, listened to the advice and the words of our health care
professionals, and because of that we helped lessen the curve", said Navajo Nation President Jonathan Nez.



NM reports 6 more COVID-19 deaths and 108 additional cases on May 28
As of today (5/28), the total positive cases and total deaths in the state are 7,364 and 335, respectively. The state has
performed 183,544 tests, there are 196 individuals currently hospitalized for COVID-19, and 2,684 COVID-19 cases have
recovered. NMDOH portal featuring epidemiologic breakdown of cases.



CVS to open 9 new COVID-19 drive-thru testing sites in New Mexico
One must register in advance starting Friday, May 29. People stay in their cars and use the pharmacy drive-thru window to
obtain a test kit and instructions. A CVS Pharmacy employee will watch the self-swab process to make sure that it is utilized
correctly, and tests will then be sent to an independent lab to be processed. The test results will be available in about three
days. The article lists the 9 locations.



Vast creativity emerges from NM DOH "Mask Madness" competition
On display are more than 500 masks submitted by New Mexicans for voting through June 3, with top-voted entries getting
into a March Madness style single elimination tournament, where head-to-head voting will decide winners. One can vote
once per day until June 3, after which the tournament will begin.



UNM unveils plan to ‘Bring Back the Pack’
Tuesday press release reports limited campus return from June 1 to mid-summer and gradual increase with safety in mind.
The Fall 2020 semester is currently on a hybrid plan between on-campus and virtual learning. Different UNM branch
campuses across the state will set guidelines depending on COVID-19 severity of the area.

US Highlights


California is the fourth state with at least 100,000 known cases
NY Times: In California, which has become the fourth state with at least 100,000 known infections. Gov. Gavin Newsom
seems to be moving closer to handing the reins of reopening to county public health officials. The state joins Illinois, New
Jersey and New York with the highest case counts. (subscription)



The relationship between coronavirus pandemic and crime in the United States
This article used police-recorded open crime data to understand how the frequency of common types of crime changed in 16
large cities across the United States in the early months of 2020. Seasonal auto-regressive integrated moving average
(SARIMA) models of crime in previous years were used to forecast the expected frequency of crime in 2020 in the absence of
the pandemic. The forecasts from these models were then compared to the actual frequency of crime during the early
months of the pandemic. There were no significant changes in the frequency of serious assaults in public or (contrary to the
concerns of policy makers) any change to the frequency of serious assaults in residences. In some cities, there were
reductions in residential burglary but little change in non-residential burglary. Thefts of motor vehicles decreased in some
cities while there were diverging patterns of thefts from motor vehicles.

International Highlights
 EU Governments ban hydroxychloroquine for COVID-19, trial paused as safety fears grow
France, Italy and Belgium followed a World Health Organization decision on Monday to pause a large trial of
hydroxychloroquine due to safety concerns. Hydroxychloroquine has been found to decrease survival and induce
arrhythmias. Only clinical trials will maintain use of hydroxychloroquine.

 Does new economic recovery plan create an historic moment for the European Union?
The coronavirus has so fundamentally damaged the bloc’s economy that it is now forcing European leaders to consider a
unified and sweeping response once considered unthinkable, thereby taking E.U. steps closer to a shared budget and
collective debt? The European Commission, on Wednesday proposed that it raise 750 billion euros, or $826 billion to finance
recovery from the economic collapse brought on by the virus and the worst crisis in the E.U.’s history. The proposal had all
the hallmarks of a historic moment, vesting greater authority in Brussels in ways that would make the E.U. more closely
resemble a central government.

Economics, Workforce, Supply Chain, PPE Highlights


The mental health impact of having inadequate safety equipment
Occupational Medicine: Self-report surveys were conducted in four operational environments with 3435 personnel providing
data. A total of 3401 personnel provided data on their perceptions of the adequacy of their equipment, of which 532 (15%)
stated that they had a lot of concerns that they did not have the right equipment in working order. Analysis found individuals
saying they had inadequate equipment had significantly greater odds of reporting symptoms of common mental health
disorders (CMD), 2.49 (2.03-3.06), post-traumatic stress disorder (PTSD), 2.99 (2.11-4.24), poorer global health 2.09 (1.622.70) and emotional problems 1.69 (1.38-2.06). Analyses remained significant when adjusted for confounding factors.



Face mask-induced itch
An internet survey of the general population found that 60.4% reported using face masks during the previous week; 19.6% of
these reported having itch. Those reporting sensitive skin, atopic predisposition, and facial dermatoses (acne, atopic
dermatitis or seborrheic dermatitis) reported significantly higher rates of itch development. Responders who wore masks for
longer periods more frequently reported itch. Almost 30% of itchy subjects reported scratching their face without removing
the mask or after removing the mask. Wearing face masks is linked to development of itch, and scratching can lead to
incorrect use of face masks, resulting in reduced protection.



Benefits of hiring remote postdoctoral fellows during COVID-19 pandemic
Post-doctoral fellows who work remotely may become a standard practice in academia as thousands of scientists have had to
work remotely during the pandemic. Remote work arrangements offer benefits such as decreased moving and commuting
costs and decreased distractions from co-workers. These positive experiences may encourage reluctant professors to
consider hiring remote post-docs..

Epidemiology Highlights


Hospitalization and mortality among black and white patients with COVID-19
In a large cohort in Louisiana, 76.9% of the patients who were hospitalized (N=1382) with COVID-19 and 70.6% of those who
died (N=326) were black, whereas blacks comprise only 31% of the Ochsner Health population. Black race, higher age, higher
Charleson Comorbidity Index, obesity, public insurance, and living in a low income area were associated with greater odds of
hospital admission. However, black race was not associated with higher in-hospital mortality than white race, after
adjustment for differences in sociodemographic and clinical characteristics on admission.



Peak infection rates in Africa limited by a younger and a more rural-based population
An augmented deterministic Susceptible-Infected-Recovered model predicted that rural areas and large youth populations
may limit the spread and severity of the COVID-19 epidemic in Africa and outweigh the negative impact of HIV, tuberculosis
and anemia. The large youth population may lead to more infections but most of these infections will be asymptomatic or
mild and will probably go undetected.



Characteristics of 8697 patients with COVID-19 in China: a meta-analysis
Family Medicine and Community Health: A meta-analysis of 55 unique retrospective studies showed the most common
symptoms experienced of patients with COVID-19 were fever and cough. Myalgia, anorexia chest tightness and dyspnea were
found in some patients. A relatively small percentage of patients were asymptomatic and could act as carriers of the disease.
Most patients showed normal leucocyte counts, elevated levels of C reactive protein and lymphopenia, confirming the viral
origin of the disease.

Healthcare Policy Recommendations


South Korea COVID-19 control: focus on reduced time from symptom onset to hospitalization
To date, South Korea has 0.2 COVID-19 deaths per million, the US has about 300 per million, and New Mexico has about 155
per million. This article shows how South Korea focused their surveillance system on a single metric: shortening time from
symptom onset to quarantine and hospitalization. Their target of 72 hours with rapid contact tracing both reduces
transmission and gives patients treatment as early as possible to address complications immediately as they arise.



Full travel ban might have prevented 86% of COVID-19 cases: data modelling study
The authors used disease incidence data from China and data on air travel between China and Australia during and after the
epidemic peak in China, derived from incoming passenger arrival cards. The modelled epidemic with the full ban fitted the
observed incidence of cases well, predicting 57 cases on March 6th in Australia, compared to 66 observed on this date. The
modelled impact without a travel ban results in more than 2000 cases and about 400 deaths, if the epidemic remained
localized to China and no importations from other countries occurred. The full travel bans reduced cases by about 86%, while
the impact of a partial lifting of the ban is minimal and may be a policy option.



The role of case managers during COVID-19 crisis
The paper discusses the roles and responsibilities of case managers and leaders known to address patients' needs during a
crisis, with a special focus on telehealth, tele-case management, surge capacity, redeployment, discharge planning, and
transitions of care.



Only half of Americans are ready to get vaccinated once the vaccine becomes available
Of 1056 respondents interviewed, 49% of Americans say they plan to get a vaccination, 31% say they are unsure, and 20%
said they will not. Of the latter cohort 70% are concerned about vaccine side effects and 42% about contracting the virus
from the vaccine. Black Americans and individuals over 60 years old were more likely to say they do not plan to get the
vaccine if it becomes available.

Practice Guidelines


Restarting essential surgery during COVID-19 pandemic
The authors from Harvard propose interim safety recommendations for patients with no known COVID-19/previously
infected with COVID-19 who are being considered for a surgery.



UNM project ECHO response to COVID-19: professional education and bone health guidelines
Project ECHO (Extension of Community Healthcare Outcomes), developed at the University of New Mexico in 2003, is
technology-enabled collaborative learning that uses videoconferencing to expand healthcare workforce capacity, increase
access to specialty level care, and reduce health disparities in underserved communities. There are now at least 825 ECHO
programs addressing a broad range of disease states and conditions, based in 48 states and 39 countries. Project ECHO
responded by temporarily redeploying all staff to activities devoted to best practiceCOVID-19 care forpublic health officials,
scientists, and frontline healthcare workers in the USA and abroad. Bone Health TeleECHO listed guidelines for orthopedic
care during COVID-19 pandemic with an emphasis on osteoporosis. Treatment plans include non-bisphosphonate injections
in drive-thru setting or using nursing home-visits to administer medication. Virtual platforms are offered to address the
canceled conferences across the globe and for patient care. The skills to launch and maintain an ECHO program can be
acquired through no-cost “Immersion training” provided at UNMHSC and in other countries, and now available in an online
format.



COVID-19 treatment simulation examples
NEJM: Engage in these five treatment simulations that mimic the real-life uncertainty of medicine.

Testing


Validation of modified viral detection assays across multiple specimen types
Modified CDC-based assays N1 and N2 were able to detect SARSCoV- 2 accurately across a range of sample types. The
authors compared the matrix effect on the analytical sensitivity of SARS-CoV-2 detection by qRT-PCR in nasal swabs collected
in viral transport medium, bronchoalveolar lavage, sputum, plasma, cerebral spinal fluid (CSF), stool, VTM, phosphate
buffered saline, and Hanks' Balanced Salt Solution. Initial limits of detection (LoD) were subsequently narrowed to confirm an
LoD for each specimen type and target gene. SARS-CoV-2 N1 assay detection sensitivity was comparable between specimen
types. Of the specimen types detected using the N2 assay, CSF was the most sensitive.

Drugs, Vaccines, Therapies, Clinical Trials


No clinical difference between Remdesivir for 5 days or 10 days in an open-label trial
This is a randomized, open-label, phase 3 trial involving hospitalized patients with confirmed SARS-CoV-2 infection, oxygen
saturation of 94% or less while they were breathing ambient air, and radiologic evidence of pneumonia. Patients were
randomly assigned in a 1:1 ratio to receive intravenous remdesivir for either 5 days or 10 days. All patients (N=397) received
200 mg of remdesivir on day 1 and 100 mg once daily on subsequent days. The primary end point was clinical status on day
14, assessed on a 7-point ordinal scale. After adjustment for baseline clinical status, patients in the 10-day group had a
distribution in clinical status at day 14 that was similar to that among patients in the 5-day group (P=0.14). The most common
adverse events were nausea (9% of patients), worsening respiratory failure (8%), elevated alanine aminotransferase level
(7%), and constipation (7%).



Anti-platelet therapy might be effective in improving the ventilation/perfusion ratio
A proof-of-concept study in Italy matched 5 control patients with 5 SARS-CoV-2 patients having severe respiratory failure
requiring helmet continuous positive airway pressure (CPAP), who had bilateral pulmonary infiltrates and a pro-thrombotic
state identified as a D-dimer > 3 times the upper limit of normal. Beyond standard of care, treated patients received 25
micro-g/kg/body weight tirofiban as bolus infusion, followed by a continuous infusion of 0.15 micro-g/kg/body weight per
minute for 48 hours. Before tirofiban, patients received acetylsalicylic acid 250 mg infusion and oral clopidogrel 300 mg; both
were continued at a dose of 75 mg daily for 30 days. Fondaparinux 2.5 mg/day sub-cutaneous was given for the duration of

the hospital stay. All controls received prophylactic or therapeutic dose heparin, according to local standard operating
procedures. Treated patients experienced a mean (SD) reduction in alveolar-arterial O2 gradient of -32.6 mmHg (61.9, P =
0.154), -52.4 mmHg (59.4, P = 0.016) and -151.1 mmHg (56.6, P = 0.011; P = 0.047 vs. controls) at 24, 48 hours and 7 days
after treatment. PaO2/FiO2 ratio increased by 52 mmHg (50, P = 0.172), 64 mmHg (47, P = 0.040) and 112 mmHg (51, P =
0.036) after 24, 48 hours and 7 days, respectively. All patients, but one, were successfully weaned from CPAP after 3 days.
This was not true for the control group. No major adverse events were observed.



Modeling of repurposed drugs in S-protein inhibition
The study conducted virtual screening using docking calculations, a molecular modeling technique that predicts how a
protein interacts with small molecules. FDA approved drugs (n=9091) were screened. The 24 best-scored ligands had binding
energy below –8.1 kcal/mol and were selected as potential candidates to inhibit the SARS-CoV-2 S-protein by preventing the
human cell infection and their replication. Ivermectin was among those promising candidates that controlled replication in
vitro.



S-Hydroxychloroquine as a potentially superior drug compared to R-HCQ
Preprint: The clinical outcome from previous CQ or HCQ trials were the collective manifestation of both R and S enantiomers
with inherent different pharmacodynamic, pharmacokinetic properties, and toxicity liabilities. S-chloroquine (S-CQ) and Shydroxychloroquine (S-HCQ) were found to be 27% and 60% more active against SARS-CoV-2, as compared to R-CQ and RHCQ, respectively.



Stem cell therapy: Consideration as a potential treatment for SARS-COV-2-induced lung injury
Acute lung injury (ALI), results from a wide variety of lung injuries. Viral infection is the main cause of morbidity and mortality
in ALI and acute respiratory distress syndrome (ARDS) patients. Future research on stem cell-based therapy for lung injury
caused by influenza viruses including SARS-CoV-2 is therefore required.



Intravenous tocilizumab has no clinical impact on SARS-CoV-2 pneumonia patients
Tocilizumab, a humanized monoclonal antibody, targets IL-6 receptors blocking downstream pro-inflammatory effects of IL-6.
In a prospective study of 51 Italian patients hospitalized with severe COVID-19 pneumonia, tocilizumab intravenous
treatment revealed a significant drop in body temperature and CRP value and increase in lymphocyte counts. Tocilizumab
treatment therefore seem to have beneficial effect on fever and inflammatory markers without any impact on clinical
outcome.



Hydroxychloroquine and chloroquine safety issues
A multinational registry analysis showed that after controlling for multiple confounding factors, when compared with
mortality in the control group (9.3%), hydroxychloroquine (18.0%; hazard ratio 1.335, 95% CI 1.223-1.457),
hydroxychloroquine with a macrolide (23.8%; hazard ratio 1.447, 1.368-1.531), chloroquine (16.4%; hazard ratio 1.365,
1.218-1.531), and chloroquine with a macrolide (22.2%; hazard ratio 1.368, 1.273-1.469) were each independently
associated with an increased risk of in-hospital mortality. Risk of de-novo ventricular arrhythmia during hospitalization
increased compared with the control group (0.3%), hydroxychloroquine (6.1%; hazard ratio 2.369, 1.935-2.900),
hydroxychloroquine with a macrolide (8.1%; hazard ratio 5.106, 4.106-5.983), chloroquine (4.3%; hazard ratio 3.561, 2.7604.596), and chloroquine with a macrolide (6.5%; hazard ratio 4.011, 3.344-4.812).



Lopinavir-ritonavir (Kaletra) did not accelerate recovery or improve mortality rates
The study’s 199 patients with confirmed severe acute respiratory syndrome coronavirus 2 infection were randomly assigned
to receive standard care plus 400mg of lopinavir and 100mg of ritonavir twice a day for 14 days or standard care alone. For
both groups the time to clinical improvement— the primary end point—was a median of 16 days. Researchers stopped the
intervention early for 13 patients who experienced mainly gastrointestinal adverse events.



79 New COVID-19 Trials registered yesterday and today at clinicaltrials.gov
Treatment trials: Tannin, IgG/IgM Antibody Test, Reactogenicity and immunogenicity of mRNA-1273, Antigen Testing, EIDD2801, Hydroxychloroquine & Axithromycin, Hydroxychloroquine with Lopinavir & Ritonavir, Ozanimod, TAF/FTC for preexposure, SCB-2019, Dornase Alfa, Ivermectin, TD-0903, LSALT Peptide, Stellate Ganglion Block, COLchicine vs. Ruxolitinib,
Viral specific T-cells, Tocilizumab, Pulmozyme, Ivermectin & Doxycycine, Acai Berry, Favipiravir. At time of writing, a total of

1686 were active, 101 completed, and 3 posted results.

Other Science


Apolipoprotein E (APOE) e4 genotype associated with severe COVID-19 in a UK cohort
The Journals of Gerontology: Series A: This UK Biobank genetic study in patients of European ancestry found that the APOE
e4e4 allele is associated with an increased risk of severe COVID-19 infection (OR=2.31, 95% CI: 1.65-3.24 p=1.19E-06),
independent of pre-existing dementia, cardiovascular disease, and type-2 diabetes. In older adults, pre-existing dementia is a
major risk factor for COVID-19 severity (about 3-fold). The APOE e4 genotype is associated with both dementia and delirium,
with the e4e4 (homozygous) genotype associated with a 14-fold increase in risk of Alzheimer’s. APOE e4 affects lipoprotein
function (and subsequent cardio-metabolic diseases) and moderates' macrophage pro-/anti-inflammatory phenotypes. SARSCoV-2 uses the ACE2 receptor for cell entry. ACE2 is highly expressed in type II alveolar cells in the lungs, where APOE is one
of the highly co-expressed genes.



Out-of-hospital cardiac arrest (OHCA) doubles during the COVID-19 pandemic in Paris, France
Lancet Public Health: This observational study (n=30,768) compared OHCA case incidence and patient characteristics from a
6-week period during the COVID-19 pandemic in Paris and its suburbs (March 16 to April 26, 2020) with corresponding
periods over the preceding 8 years. A transient two-fold increase in OHCA incidence, coupled with a reduction in survival,
was observed during the specified time period of the pandemic when compared with the equivalent time period in previous
years with no pandemic. Although this result might be partly related to COVID-19 infections, indirect effects associated with
lockdown and adjustment of health-care services to the pandemic are probable. The authors advocate that these factors
should be taken into account when considering mortality data and public health strategies.



Laboratory findings of COVID-19: a systematic review and a meta-analysis
Scandinavian Journal of Clinical and Laboratory Investigation: A 28-paper systematic review showed the most prevalent
laboratory findings significantly associated with severity were increased C-reactive protein (CRP; 73.6%, 95% CI 65.0-81.3%),
followed by decreased albumin (62.9%, 95% CI 28.3-91.2%), increased erythrocyte sedimentation rate (61.2%, 95% CI 41.381.0%), decreased eosinophils (58.4%, 95% CI 46.5-69.8%), increased interleukin-6 (53.1%, 95% CI 36.0-70.0%), lymphopenia
(47.9%, 95% CI 41.6-54.9%), and increased lactate dehydrogenase (LDH; 46.2%, 95% CI 37.9-54.7%). A 7-study meta-analysis
with 1905 patients showed that increased CRP (OR 3.0, 95% CI: 2.1-4.4), lymphopenia (OR 4.5, 95% CI: 3.3-6.0), and
increased LDH (OR 6.7, 95% CI: 2.4-18.9) were significantly associated with severity.



Low SARS-CoV-2 RNA contamination of inanimate surfaces in emergency unit
Clinical Microbiology and Infection: 26 samples were taken from emergency unit and sub-intensive care ward. RT-PCR was
run and found 2 of 26 surfaces were positive for low-level SARS-CoV-2 RNA. These two collections were from the external
surface of CPAP helmets. The study concluded that infection spread through inanimate objects may be less extensive than
previously reported.



Long-term outcomes in SARS and MERS survivors: a meta-analysis
Journal of Rehabilitation Medicine: 28 studies were included in the analysis on SARS (severe acute respiratory syndrome) and
MERS (Middle East respiratory syndrome) survivors. Common complications up to 6 months were: impaired diffusing
capacity for carbon monoxide (prevalence 27%, 95% CI 15-45%); and reduced exercise capacity ((mean 6-min walking
distance 461 m, CI 450-473 m). The prevalence of post-traumatic stress disorder (39%, 95% CI 31-47%), depression (33%,
95% CI 20-50%) and anxiety (30%, 95% CI 10-61) beyond 6 months were considerable. Low scores on Short-Form 36 were
identified at 6 months and beyond.

Contributing team members: Christophe G. Lambert, Shawn Stoicu, Ingrid Hendrix, Lori Sloane, Mari Anixter,
Anastasiya Nestsiarovich, Praveen Kumar, Nicolas Lauve, Jenny Situ, Ariel Hurwitz, Elly Munde, Perez Olewe,
Kristine Tollestrup, Orrin Myers, Douglas J. Perkins.

Disclaimer: The UNM Global Health COVID-19 Briefing is provided as a public service. Sources include not only
peer-reviewed literature, but also preliminary research manuscripts that have not been peer reviewed along
with lay news media reports. The peer-review process often results in manuscript improvement, with
corrections made for errors and unsubstantiated conclusions being corrected. Furthermore, many headlines
and summaries in the briefing are written by student volunteers and others who may lack subject matter
expertise in this rapidly evolving field. As such, the headlines and summaries should not be regarded as
conclusive. Instead, readers are encouraged to use the briefing to identify areas of interest and then use the
embedded links to read and critically evaluate the primary sources.

